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1.1 Dopamine, a neurotransmitter in the central nervous system
Neurotransmitters serve to transmit signals between neurons, which are separated by a
synaptic cleft. One of the neurotransmitters is dopamine (DA), or β-(3,4-
dihydroxyphenyl)ethylamine (1). Until the mid-1950s dopamine was exclusively considered to
be an intermediate in the biosynthesis of the catecholamines noradrenaline and adrenaline.
Significant tissue levels of dopamine were first demonstrated in peripheral organs of ruminant
species.1 A short time later it was found that dopamine was also present in the brain in about
equal concentrations to those of noradrenaline.2
When a stimulus depolarises the transmembrane potential in a
spiking axon above the threshold level, an all-or-none action
potential in a spiking axon is activated. The action potential
propagates unattenuated to the nerve terminal where ion fluxes
activate a mobilisation process leading to transmitter secretion.3
The neurotransmitter binds reversibly to receptor proteins embedded in the membrane of a
neuron, which triggers a certain effect. There are two types of receptors known, presynaptic
receptors or autoreceptors which are present on the neurotransmitter ‘releasing neurons’, and
postsynaptic or heteroreceptors, which are present on the neurotransmitter ‘receiving neuron’.
The former are supposed to perform a feed-back function, and slow down the release of
neurotransmitter from these neurons when they are stimulated.4
Dopamine receptors are G-protein coupled receptors. After a receptor has been activated,
this G-protein may activate or inhibit the second messenger system causing certain biochemical
reactions to occur. In contrast to the ionotropic receptors that are linked to an ion-channel and
respond very fast to activation by a neurotransmitter (millisecond processes), G-protein coupled
receptors mediate slower responses (seconds to minutes) and in general have a modulatory
function on other signal transduction processes.4
Although dopamine also has important peripheral functions, e.g. within the regulation of
cardiovascular homeostasis, this thesis will deal with the effects of ligands on dopamine
receptors in the central nervous system (CNS). Dopamine is the predominant catecholamine
neurotransmitter in the mammalian brain and is involved in the regulation of a number of
physiological activities, i.e. movement, emotion and hormone secretion. These activities are
associated with three principal dopaminergic pathways: (1) The nigrostriatal pathway controls
movements; partial degeneration of this system contributes to the pathogenesis of Parkinson’s






is thought to contribute to the aetiology of schizophrenia. (3) The tuberoinfundibular pathway
regulates e.g. prolactin secretion from the pituitary and influences lactation and fertility.5
1.2 General aspects of dopamine neurotransmission in the central nervous system
1.2.1 Biosynthesis of dopamine
The synthesis of dopamine originates from the precursor the amino acid L-tyrosine, which
must be transported across the blood-brain barrier into the dopaminergic neuron. The rate
limiting step in the synthesis is the conversion of L-tyrosine to L-dihydroxyphenylalanine
(L-DOPA) by the enzyme tyrosine hydroxylase (TH). L-DOPA is subsequently converted to
dopamine by aromatic L-amino acid decarboxylase. The latter enzyme turns over so rapidly that












Chart 1.1 Biosynthesis of dopamine. Dopamine (1); L-Tyrosine (2); L-3,4-dihydroxyphenylalanine
(3, L-DOPA); TH, tyrosine hydroxylase; AAAD, aromatic L-amino acid decarboxylase.
Under normal conditions it is not feasible to augment dopamine synthesis significantly by
increasing brain levels of L-tyrosine, since the levels in the brain are already above the Km for
tyrosine hydroxylase. The activity of tyrosine hydroxylase is subject to four major regulatory
influences: (1) Dopamine functions as end-product inhibitor of TH by competing with a
tetrahydrobiopterin (BH-4) cofactor for a binding site on the enzyme. (2) The availability of BH-
4 may also play a role in regulating TH activity. (3) Presynaptic dopamine receptors also
modulate the rate of tyrosine hydroxylation. These receptors are activated by dopamine released
from the nerve terminal, resulting in feedback inhibition of dopamine synthesis. (4) Dopamine
synthesis also depends on the rate of impulse flow in the nigrostriatal pathway. On the other
hand it is possible to enhance dramatically the formation of dopamine by increasing the levels of
L-DOPA because of the high activity of aromatic L-amino acid decarboxylase and the low
endogenous levels of L-DOPA normally present in the brain.1
1.2.2 Dopamine re-uptake and metabolism
Once the dopamine that is released into the synaptic cleft has exerted its action on the
various dopamine receptors, these actions have to be terminated to prevent continuous
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stimulation of these receptors. This inactivation is brought about by re-uptake mechanisms and
by metabolism of dopamine.
Dopamine nerve terminals possess high-affinity dopamine uptake sites that are important
in termination transmitter action and in maintaining transmitter homeostasis. Uptake is
accomplished by a membrane carrier that is capable of transporting dopamine in either
direction, depending on the existing concentration gradient. The dopamine transporter recycles
extracellular dopamine by actively pumping it back into the nerve terminal. About 70-80 % of
the dopamine, which is present in the synaptic cleft, is inactivated by this process. Certain drugs,
such as cocaine, are able to block the action of the dopamine transporter, thereby sustaining the
presence of dopamine in the synaptic cleft and its action on dopamine receptors.
After re-uptake by the nerve terminal a part of the released dopamine is converted to
dihydroxyphenylacetic acid (DOPAC, 5) by intraneuronal monoamine oxidase (MAO) and
aldehyde dehydrogenase (AD). Released dopamine is also converted to homovanillic acid
(HVA, 6), probably at an extraneuronal site through the sequential action of catechol-O-
methyltransferase (COMT) and MAO. In rat brain, DOPAC is the major metabolite and




























Chart 1.2 Neuronal metabolism of dopamine. Dopamine (1); 3,4-dihydroxyphenyl acetaldehyde
(4); 3,4-dihydroxyphenylacetic acid (DOPAC, 5); homovanillic acid (HVA, 6);
3-methoxytyramine (3-MT, 7); 3-methoxy-4-hydroxyphenyl acetaldehyde (8); MAO,





1.3.1 General structural features of G-protein-coupled receptors
Upon release from dopaminergic neurons, dopamine exerts its action by interacting with
specific dopamine receptors. With molecular biological techniques five subtypes of dopamine
receptors have been identified so far. These receptors have been characterised anatomically, and
to a certain extent biochemically and pharmacologically. All currently identified dopamine
receptor subtypes belong to the superfamily of G-protein-coupled receptors (GPCRs).
A wide variety of membrane receptors for hormones and neurotransmitters are coupled to
guanine-nucleotide-binding regulatory ‘G’ proteins, which upon activation by receptors,
stimulate or inhibit various effectors such as enzymes or ion channels. Among the family of
receptors coupled to G-proteins are those for catecholamines, acetylcholine and related
muscarinic ligands, tachykinins, and for the pituitary glycoprotein hormones and many more.6
The exact molecular structures of GPCRs are unknown, since attempts to crystallise these
proteins have failed thus far. Nevertheless, biophysical, biochemical and molecular biological
studies on various GPCRs suggest that these receptors have many structural features in common.
The common features are: (1) a cell surface receptor; (2) an effector, such as an ion channel or
the enzyme adenylyl cyclase; and (3) a G-protein, that is coupled to both the receptor and its
effector.7 All these receptors are made up of a single chain containing amino acid residues of
which the number of residues differ for each receptor subtype. The amino-terminus, which has
no signal sequence, may contain sites for N-linked glycosylation, which is the case for the
dopamine receptors; the carboxy-terminus has typical sites for phosphorylation by protein
kinase A and other kinases. Seven stretches of 22-28 hydrophobic conserved residues, separated
by hydrophilic segments, are found in each of the members of the family of proteins, as has been
seen earlier in the well-characterised rhodopsins, which are also coupled to a GTP binding
protein. This similarity has led to the suggestion that these receptors share with
bacteriorhodopsin its peculiar membrane topology by which the seven conserved hydrophobic
segments form transmembrane domains, possibly constituting α-helices, although other
configurations are also imaginable. The N-terminal region, by virtue of its glycosylation, is
extracellular and the carboxy-terminal domain is intracellular. The various portions between the
seven hydrophobic stretches are either extra- or intracellular. The third intracellular and the
carboxy-terminal segments display an extensive variability in length and sequence, which has
led to the hypothesis that these parts of the 7 transmembrane G-protein coupled receptors are
responsible for the selective interaction with the various regulatory G-proteins.6 All GPCRs
cloned so far have been shown to possess a substantial degree of homology in their amino acid
sequences, especially in the transmembrane regions.
The binding site for the endogenous ligand (the ‘active site’) is believed to be situated
within the core formed by the seven transmembrane domains.7 Binding of the endogenous
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ligand to the active site presumably induces conformational changes in the receptor molecule,
which trigger via the G-protein an intracellular response, e.g. the activation of a second
messenger system. In this way, the ‘information’ carried by the ligand is transduced over the
plasma membrane into the cell (for reviews and references on GPCRs, see refs. 6-8).
Figure 1.1 Schematic model for the insertion of G-protein-coupled receptors in the plasma
membrane. The seven transmembrane domains are shown as cylinders spanning the lipid
bilayer. The intra- and extracellular loops are represented by black ribbons. The ligand
binding site is formed by the interaction of several transmembrane domains. Coupling to
transducing and desensitisation systems involves the cytoplasmic loops. Glycosylation
(represented with a Y) of the N-terminus is required for proper insertion of the receptors
in the membrane but not for ligand binding. Figure adapted from ref. 6.
1.3.2 Dopamine receptor classification
The application of biochemical, pharmacological and physiological techniques to the
study of dopamine receptors showed clearly that there were multiple receptors for dopamine,
and in 1978 it was proposed that there were two subtypes of the dopamine receptor (D1 and
D2).9 The application of molecular biological techniques in the late 1980s showed that there
were at least five dopamine receptor subtypes (D1, D2, D3, D4 and D5).10-18
On the basis of structural, pharmacological, functional and distributional similarities, all
dopamine receptor subtypes fall into one of the two initially recognised receptor categories, here
designated dopamine D1- or dopamine D2-like receptors. Dopamine D5 receptors share extensive
similarities with dopamine D1 receptors, while dopamine D3 and D4 receptors more closely
conform to the features of dopamine D2 receptors. The properties of the two subfamilies closely
resemble those of the dopamine D1 and D2 receptor subtypes as originally defined by Kebabian
and Calne.9 The most important characteristics of the cloned human dopamine receptor subtypes
are summarised in Table 1.1.
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Table 1.1 Summary of the characteristics of cloned human dopamine receptor subtypes.
D1-like D2-like
D1 D5 D2 D3 D4
Gene
Chromosome localisation 5q35.119 4p16.319 11q22-2319 3q13.319 11p15.519
Introns no12-14 no10,18 yes15 yes17 yes16
Expression – – D2A/D2B – D4.2-D4.10
Protein
Amino acids 44612-14 47710,18,20 443/41415 40017 38716
3rd Cytoplasmatic loop short short long long long
C-terminus long long short short short
Sequence homologya D1 100 82 47 45 42
D5 100 44 40 45
D2 100 77 51
D3 100 40
D4 100
Localisationb, 21 Cput, NAc,
ICj, OT











Dopamine affinity (nM)c 2300 230 2000 30 450
Agonist SKF 38393 SKF 38393 N-0923 PD 128907 PD 168077
Antagonist SCH 23390 SCH 23390 Raclopride S 14297 L-745,870
Biochemistryd
G-protein coupled yes yes yes yes/? yes
cAMP + + – n.e./– n.e./–
IP3 + ? + n.e. n.e.
Ca2+ + ? – – –
Arachidonic acid ? ? + n.e./– +
Dopamine release ? ? – n.e./– n.e.
Mitogenesis ? ? + n.e./+ ?
Acidification ? ? + + +
Footnotes: a Sequence homology in transmembrane domains, expressed as percentages. b Based on
rat brain mRNA distribution data, only the areas with a high density are mentioned. Abbreviations: Cput,
Introduction
7
caudate putamen; NAc, nucleus accumbens; ICj, islands of Calleja; OT, olfactory tubercle; Hipp,
hippocampus; Hyp, hypothalamus; Thal, thalamus; Pit, pituitary; SN, substantia nigra; VTA, ventral
tegmental area; Sept, septum; Cer, cerebellum; FC, frontal cortex; Amyg, amygdala; Mes,
mesencephalon; MO, medulla oblongata. c Values in the presence of Gpp(NH)p (taken from ref. 22).
d
 Abbreviations: cAMP, cyclic adenosine monophosphate; IP3, inositol triphosphate; +, increase;
–, decrease; n.e., no effect; ?, unknown; n.e./– and n.e./+, in the literature there is a controversy about the
effect (taken from ref. 23).
In addition to elucidating the molecular features of GPCRs, molecular cloning techniques
have also allowed for the expression of GPCRs in cells that normally do not express such
receptors. Thus, mammalian cell lines can be transiently or permanently transfected with
cDNAs encoding the different dopamine receptor subtypes. Because these cells usually express
a single receptor subtype in high density, they are very suitable for determining receptor binding
affinities of drug candidates. Since most newly synthesised target compounds presented in the
subsequent chapters of this thesis have been evaluated for their ability to bind to cloned human
dopamine D2 and D3 receptors, the characteristics of these two receptor subtypes will be
described in more detail in the next sections. For reviews and references on the other dopamine
receptor subtypes, see refs. 21,24-26.
1.3.3 Dopamine D2 receptors
Based on the presumed structural homology between different GPCRs a rat genomic
library was screened by Bunzow et al.15 They used the DNA sequence encoding the hamster β2-
adrenergic receptor as a hybridisation probe. Ultimately a cDNA was isolated which coded for a
415 amino acid protein, which possessed a relative molecular mass similar to that for the
deglycosylated form of the dopamine D2 receptor as determined by SDS-PAGE. Another
conformation that this cloned receptor was the dopamine D2 receptor was the fact that the
mRNA distribution parallels that of the dopamine D2 receptor. Several structural features of the
protein deduced from this cDNA demonstrated that it belongs to the family of GPCRs. First, a
hydrophobicity plot of the protein sequence shows the existence of seven stretches of
hydrophobic amino acids, which could represent seven transmembrane domains. Second, the
primary amino acid sequence shows a high degree of similarity with other GPCRs. Third, the
protein has several structural characteristics common to the other members of the family of
GPCRs. There are three consensus sequences for N-linked glycosylation in the N-terminus with
no signal sequence. Aspartate 80 found in transmembrane domain II is conserved in all known
GPCRs. In transmembrane domain III Asp114 corresponds to an Asp residue found in receptors
that bind cationic amines. Phosphorylation has been proposed as a means of regulating receptor
function. A potential site for phosphorylation by protein kinase A exists at Ser228 in the third
cytoplasmic loop. The cloned protein contains a large cytoplasmic loop between transmembrane
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domains V and VI with a short C terminus. This structural organisation is similar to other
receptors, which are coupled to Gi.15
In situ hybridisation revealed the distribution of dopamine D2 receptor mRNA in the rat
brain. High abundance was found in regions which are classically associated with dopaminergic
neurotransmission, including the caudate putamen, nucleus accumbens, olfactory tubercle,
pituitary, substantia nigra pars compacta and ventral tegmental area.27,28
When the receptors were expressed in mouse fibroblast cells it was possible to determine
the pharmacological features of the receptor. It turned out that the expressed receptors possessed
features typical of the native striatal dopamine D2 receptor. When all of the drug Ki values were
compared, their rank order of potency (spiperone > (+)-butaclamol > haloperidol > sulpiride >>
(–)-butaclamol) agrees closely with the published values for the dopamine D2 receptor.29
Expression of the receptor in other cell lines has revealed that the receptor interacts
productively with a G-protein, probably Gi to inhibit adenylyl cyclase activity,30 and also
appeared to inhibit prolactin secretion.29 Taken together, these findings strongly suggest that the
cloned protein indeed corresponded to the classical dopamine D2 receptor (for reviews and
references see ref. 29).
After cloning of the rat dopamine D2 receptor by Bunzow et al.15 the next step was the
cloning of the human dopamine D2 receptor.11,31 The human and rat dopamine D2 receptors are
encoded by highly related genes, and are pharmacologically highly related.11 The two receptors
differ in only 18 amino acid substitutions and by 1 amino acid in length, the human form lacking
an isoleucine in the third cytoplasmic loop.11 In order to determine which amino acids were
relevant in binding and effector-coupling and to test these models, dopamine D2 receptor
mutants were generated. Initially, the highly conserved Asp 80 was recognised as serving a
central role in normal receptor coupling to adenylyl cyclase.21,32 Ser 193, in particular, seems to
play a critical role in binding dopamine21,33 and Asp 114 was a prerequisite for agonist as well
as antagonist binding.21
A number of different studies have revealed that the dopamine D2 receptor exists in
alternate splice forms in rats31,34-38 and humans.31,39 The two forms of the dopamine D2 receptor
exist both in human and rat, and are generated by alternative splicing. Specifically, these forms
differ by a 29 residue peptide sequence located in the predicted intracellular domain between
transmembrane domain V and VI (cytoplasmic loop 3). The presence of this peptide
characterises the more abundant, larger form (D2L receptor); its absence defines the rarer,
shorter form (D2S receptor). The fact that the difference between the two isoforms lies in the
third cytoplasmic loop may be important for G-protein coupling. This suggests that alternative
splicing is used to fine-tune receptor interaction with Gi and Go proteins. In fact, in preliminary
expression studies, the D2S receptor inhibited adenylyl cyclase activity to a greater extent than
did the D2L receptor form, corresponding with the notion that the shorter form more effectively
couples to a Gi protein.31 Several groups tried to identify properties that may differentiate the
two dopamine D2 receptor variants by studying the mRNA expression of the two receptor
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isoforms in brain and pituitary, and as expressed in different cell lines.35-37,39-41 Both splice
variants have been detected in human anterior pituitary31,42 and in a variety of brain regions.42 In
general, the mRNA distribution of both splice variants agrees with the distribution pattern of
total dopamine D2 mRNA. However, the D2L/D2S mRNA ratio varies in different brain regions
and the short isoform is the least abundant of the two. Receptor binding experiments show that
for D2S and D2L the Ki values for the high and low affinity agonist binding are rather similar in
three cell lines tested, it is the proportions of the sites that differ. However, some compounds
seem to have a higher affinity for the dopamine D2S receptor.43,44
Presumably via coupling to different G-proteins, dopamine D2 receptors in various cell
lines revealed that they utilise different signal transduction systems (for reviews see refs. 21,
25). Inhibition of adenylyl cyclase has been detected in all cellular environments,30,45-51 but cell-
specific signalling pathways may be present as well. Beside inhibition of intracellular cAMP
production, stimulation of dopamine D2 receptors may result in: (1) enhancement of
phosphatidylinositol (PI) hydrolysis by activation of the enzyme phospholipase C;49,51
(2) increase48,49,51 or decrease51 in the intracellular Ca2+ concentration; (3) opening of K+
channels;51 and (4) extracellular release of arachidonic acid.48,52
1.3.4 Dopamine D3 receptors
In 1990 Sokoloff et al.17 cloned the cDNA encoding a novel dopamine D2-like receptor,
which was designated as dopamine D3 receptor. The human dopamine D3 receptor consisted of
400 amino acid residues and displayed a homology of 46 % with the human dopamine D2
receptor and a homology of 78 % if only the presumed transmembrane domains are
considered.53 In addition, the subtypes have more structural features in common, such as the
presence of introns in the coding sequence, a long third intracellular loop, a short carboxylic
acid terminal segment and several glycosylation sites. The existence of introns may give rise to
the expression of splice variants encoded by the same gene. Various truncated forms of the
dopamine D3 receptor mRNA, generated by alternative splicing, have been detected in rat and
human brain which do not correspond to a functional receptor.19,54
The anatomical distribution of the dopamine D3 receptor mRNA partially overlaps but
markedly differs from that of dopamine D2 receptor mRNA. The dopamine D3 receptor is
mainly expressed in discrete brain areas belonging to or related to the limbic system, whereas
dopamine D1 and D2 receptors are widely expressed in all major dopaminoceptive areas.17 Both
dopamine D2 and D3 receptors are expressed by dopamine neurons belonging to the A9 and A10
cell groups and it has been suggested that both act as autoreceptors. Such a role for the
dopamine D3 receptor is consistent with its high apparent affinity for dopamine. The
pharmacological profile of the dopamine D3 receptor is comparable to that of the dopamine D2
receptor, and supports a possible role as an autoreceptor. Thus, all dopamine D2 receptor
agonists and antagonists bind with good affinities to dopamine D3 receptors as well, but some
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compounds, previously designated as putative dopamine D2 autoreceptor agonists (e.g. 7-OH-
DPAT) or antagonists (e.g. (+)-AJ 76 and (+)-UH 232), show preference for the dopamine D3
receptor. Given this pharmacological profile it would favour a role for the dopamine D3 receptor
as an autoreceptor. If so, it could play a role in regulating impulse flow, as well as
neurotransmitter synthesis and release. However, the function of the dopamine D3 receptor is
still subject of debate. Several studies have given some insight into this debate, using the
dopamine D3 receptor preferring ligands R-(+)-7-OH-DPAT and PD128907 (agonists) or
U-99194A (antagonist). Some studies indicate that the dopamine D3 receptor is an autoreceptor
involved in the presynaptic regulation of dopamine release.55-62 These data, however, could not
be confirmed by dopamine D2 and D3 knock-out mice. Experiments with dopamine D2 receptor-
deficient mice strongly suggest that only D2 but not D3 receptors are involved in the
autoreceptor-mediated inhibition of the evoked release of [3H]-dopamine.63 These data are
confirmed by experiments with D3-receptor knock-out mice.64
Other studies indicate that the dopamine D3 receptor is located postsynaptically and is
involved in locomotor activity and behaviour. Experiments with dopamine D3 receptor
agonists65-72 and antagonists73-76 show that these receptors have inhibitory effects on locomotor
activity and behaviour. In the literature it is also described that administration of dopamine D3
receptor antisense67 and dopamine D3 mutant mice77 give hyperactivity in the animals. Svensson
et al.72,78 showed that the decrease in locomotor activity after agonist administration is not likely
to be dependent upon effects on dopamine release or synthesis.
Using [3H]-7-OH-DPAT and [3H]-PD 128907 it was possible to determine the localisation
of the dopamine D3 receptor in the brain with autoradiographic techniques.79,80 The abundance
of the dopamine D3 receptor mRNA seems to be several orders of magnitude lower than that of
dopamine D2 receptor mRNA.81 Furthermore, the dopamine D3 receptor mRNA is mainly
expressed in discrete brain areas belonging or related to the limbic system,82 whereas dopamine
D2 receptor mRNA is widely expressed in all major dopaminoceptive areas.17 Northern blot81
and in situ hybridisation17 analyses showed that dopamine D3 receptor mRNA is widely
expressed in the olfactory tubercle-islands of Calleja complex, antero-medial part of the nucleus
accumbens, the bed nucleus of the stria terminalis, amygdaloid, septal, medial mammillary or
anterior thalamic nuclei and hippocampal formation. Since the dopamine D3 receptors are
mainly expressed in these ’limbic’ areas of the brain it is suggested that these receptors mediate
cognitive, emotional, neuro-endocrine and autonomic functions.81 Hence, these receptors are
major targets for antipsychotic drug action and anti-addictive drug therapy.
Whereas the signal transduction pathways of the dopamine D2 receptor have been
unravelled to a large extent, the biochemistry of the dopamine D3 receptor is much less clear.
Initial studies failed to demonstrate any coupling to G-proteins. Binding of agonists to dopamine
D3 receptors, expressed in various cell types, was not or only weakly affected by guanine
nucleotides, and no second messenger generation was observed.17,22,50,83-85 Such a lack of
response may, however, be due to the absence of a suitable G-protein or to an inappropriate
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expression of the dopamine D3 receptor in the recipient cells.17 Later studies have revealed
functional coupling of dopamine D3 receptors to different transduction mechanisms in various
cell lines. These mechanisms are: (1) inhibition of cAMP production,86 (2) aggregation of
melanophore pigment,87 (3) acidification of the extracellular environment,88 (4) inhibition of
Ca2+ currents,89 and (5) mitogen-activated protein kinase.90 It is interesting that the dopamine D3
receptors mimic the signalling output of dopamine D2 receptors in the same cell, but with a
lower efficacy, implying a less efficient coupling of dopamine D3 receptors. The different
efficacy of dopamine D2 and D3 receptor activation may be an important means for varying the
information resulting from dopamine neurotransmission.86
1.4 Structure-activity relationships of dopamine receptor agonists
Through the years a number of different structure-activity relationships (SARs) and
receptor models have been developed (for reviews see refs. 91, 92). Therefore this introduction
will only give a short overview of the general aspects of dopamine receptor agonist SARs.
The growing interest in unravelling the mechanism of action of dopamine and related
compounds at the molecular level started with the considerations of the conformation(s) of the
dopamine molecule when bound to the receptor site. Dopamine itself is a conformationally
flexible molecule that can adopt specific conformation(s) needed to achieve appropriate three
dimensional interaction with various groups located at or near the recognition (receptor) site(s).
When the conformation of the ethylamine side-chain with respect to the aromatic nucleus
is considered as the starting-point, the dopamine molecule may exist either in a trans (extended)
conformation, or in a cis (gauche) conformation. Single crystal x-ray analysis of dopamine
hydrochloride indicates that the ethylamine chain is in a nearly completely extended
conformation which resides on a plane almost perpendicular to the plane of the catechol ring.93
Cannon94,95 defined α- and β-conformers of dopamine, in which the catechol ring is
coplanar with the ethylamine side-chain (chart 1.3). In the α-conformer the meta-OH group is
on the edge of the ring closer to the ethylamine chain, whereas in the β-conformer the meta-OH
is on the edge of the ring away from the side-chain. Concluding from several studies with
dopamine analogues, which simulate the gauche conformation leading to inactive compounds,
















Chart 1.3 Gauche conformation of dopamine (1) and the two rotamers of the extended
conformation of dopamine (1 α-conformer and 1 β-conformer), and the corresponding
2-aminotetralins S-(–)-5-OH-DPAT (9) and R-(+)-7-OH-DPAT (10).
Studies with hydroxylated 2-aminotetralin analogues (among others using compounds 9
and 10) and phenylethylamine analogues revealed that the first possessed a higher potency.96,97
Apparently, the near co-planar arrangement is required for higher dopamine receptor agonist
activity.
There are two main routes along which the development of dopamine agonists has initially
proceeded, namely rigidification of the dopamine molecule (1), and dissection of one of the first









11 R1 = OH, R2 = Me
12 R1 = H,    R2 = n-Pr
Chart 1.4 Chemical structures of dopamine (1), apomorphine (11) and 11-hydroxy-N-n-
propylnoraporphine (12).
The rigidification of the dopamine molecule led to a number of dopamine receptor
agonists in which the dopamine molecule, with its phenylethylamine moiety, is readily
recognisable. In these dopamine agonists the amine moiety is either a part of a cyclic system,
e.g. benzo[f]quinolines, naphthoxazines, and benzopyranoxazines, or an exocyclic amine, e.g.


































Chart 1.5 Some approaches for the rigidification of the dopamine ethylamine side chain. R-groups
are usually -H or -OH.
SAR studies with these different classes of dopamine receptor agonists have led to the
identification of a pharmacophore for activation of dopamine D2 (-like) receptors consisting of
the meta-hydroxyphenylethylamine structure. 2-Aminotetralins, hydroxylated at the 5- or
7-posistion, are potent dopamine receptor agonists, but their 6- or 8-hydroxylated analogues are
less potent.98 8-Hydroxy-(N,N-di-n-propylamino)tetralin (8-OH-DPAT) is a potent serotonergic
agent. Also dihydroxylated compounds like 5,6-di-OH-DPAT, which possess the catechol
moiety also present in dopamine, are potent dopaminergic agents.
McDermed et al.99,100 found that the interaction of dopamine receptor agonists with
dopamine receptors is highly stereoselective. They observed that for compounds which are
α-conformers the S-enantiomer is the most active (as is the case in S-(–)-5-OH-DPAT, 9),
whereas for β-conformers the R-enantiomer is the most active (as is the case in R-(+)-7-OH-
DPAT, 10). Their assumption then was that in order to achieve the proper orientation of the
amino moiety and meta-OH groups, relative to the ethylamine side-chain, with respect to their
presumed binding groups on the dopamine receptor surface, the β-conformer must be rotated
with respect to the α-conformer (Chart 1.6). As a result of such a rotation the amine groups are







Chart 1.6 Superimposition of S-(–)-5-OH-DPAT (9) with R-(+)-7-OH-DPAT (10).
McDermed and colleagues have also included a region in the receptor preventing the
interaction with compounds having a steric bulk in this region.
In an extension of the McDermed model Wikström and colleagues,101,102 applied to the
dopaminergic monohydroxylated 3-phenylpiperidines and the octahydrobenzo[f]quinolines,
have found that there is a relationship between the absolute configuration, the ring position of
the hydroxyl group and the size of the N-alkyl substituent. In their model there are now two
different directions possible for the N-alkyl substituents, namely ‘upwards’ and ‘downwards’
(Chart 1.7). An assumption they made is that, due to the different directions in which the
N-alkyl substituents point, the space available for the N-substituent of compound 14 might be
more restricted than for the corresponding isomer 13. And indeed, they have found that the N-
substituent ‘downwards’ is sterically restricted to maximally an n-propyl group, whereas the












Chart 1.7 Wikström’s modification of McDermed’s model. The structures of 7- (13) and 9-
hydroxyoctahydrobenzo[f]quinolines (14) superimposed.
The distance from the amine-nitrogen to the hydroxyl-oxygen (meta or para) has been
studied in several classes of dopamine agonists. The distances which were found vary
considerably between these studies, which made clear that an optimal distance is hard to define.
The nitrogen atom to meta-hydroxyl distance varied from 5.5 to 7.3 Å, the nitrogen to para-
hydroxyl varied from 7.0-7.8 Å.91 Therefore, it can be concluded that any distance between the
nitrogen and the meta-hydroxyl that is less than that of dopamine in its fully extended form may
be acceptable to a minimum of 5.5 Å.
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Although some studies suggest the opposite,103 it is generally believed that the nitrogen
atom of a dopamine agonist interacts with the receptor in the protonated (ammonium) form.
This idea is supported by studies with permanently charged dopamine analogues.104
Furthermore, at physiological pH, dopamine exists mainly in the protonated form.105
In general, increasing the lipophilicity brings about increased potency for dopamine
agonists. However, this is only true for compounds within the same series. When comparing
compounds from different structural classes, other factors like conformation and
stereochemistry are of primary importance for dopamine agonist activity. The oft-quoted rule106
that an octanol-water partition coefficient, logPoct, of approximately 2 log units is optimum for
ready entry into the brain is derived from studies on biological activity and not from rates of
permeation nor from equilibria. Gratton et al.,107 however, found that even if there is a parabolic
relationship between the logarithm of a permeability surface area (logPS) and logPoct, this
relationship is not good enough to use predictively.
The development of SARs for dopamine agonists was accompanied by the development of
dopamine receptor models with computer programs. Basically, two kinds of dopamine receptor
models emerged: indirect models and direct models. Indirect models take a series of (analogous)
agents (agonists or antagonists) with certain receptor-binding characteristics as a starting point,
and describe the receptor binding site as a collection of ‘areas’ with certain properties.102,108-112
Later, the amino acid sequence and structure of the various dopamine receptor proteins became
known with molecular biological techniques, which enabled the development of direct
models.113-115 These models take the receptor protein as a starting point, and describe the
receptor binding site in terms of amino acids with different physical and sterical properties.
Despite the development of these models for the different dopamine D2-like receptors, it is still
difficult to design selective ligands, because there is a high similarity in the transmembrane
segments of the dopamine D2 like receptors and the crystal structure of the receptor is not
known yet. Since the models developed are all based on known compounds, their predictability
declines when new, not included, compounds are tested in this model.
1.5 Pathogenesis of the dopaminergic system
Both movement and psychotic disorders in humans have been associated with
disturbances in the functioning of the dopaminergic system. Examples of the motor disturbances
are Parkinson’s disease, Huntington’s disease and Gilles de la Tourette’s syndrome. These
movement diseases can be categorised into either hypo- or hyperkinetic disorders. In this
paragraph Parkinson’s disease and schizophrenia with their current treatment will be discussed.
Also drug abuse and its possible treatment will be discussed, since selective dopamine D3




1.5.1.1 Pathology of Parkinson’s disease
Parkinson’s disease is a progressive neurodegenerative disorder of the basal ganglia,
which most often becomes apparent after the age of 55. It is a prototypic hypokinetic disorder,
with tremor, rigidity, bradykinesia, and akinesia as the most prominent features.117 Depression
and a general slowing down of intellectual processes also occur, but are less well-defined. The
neurological and psychiatric symptoms usually worsen with time (for review: ref. 118). The
neuropathology of Parkinson’s disease reveals a striking loss of the dopaminergic neurons of the
nigrostriatal pathway terminating preferentially in the caudate nucleus and putamen.119,120
Although the nigrostriatal system has a large reserve (only after a decline of approx. 70-80% of
these cells, Parkinson’s disease symptoms arise), progressive loss of these systems ultimately
leads to Parkinson’s disease, with its well-known movement disorders (‘shaking palsy’). In
contrast with some other neurodegenerative diseases (e.g. Huntington’s disease), for Parkinson’s
disease no genetic component has been discovered yet. Usually the disease is not diagnosed
before the first symptoms appear.
The control of normal motor behaviour is under influence of the basal ganglia through a
so-called reinforcing basal ganglia-thalamocortical ‘motor circuit’. Based on current data from a
variety of experimental fields, a functional model of this ‘motor circuit’ has been proposed, as
depicted, greatly simplified, in Figure 1.2.
First, there is a pathway called the ‘direct’ pathway consisting of neurones containing
GABA and substance P. Activation of this pathway tends to disinhibit the thalamic stage of the
circuit. The second pathway is the ‘indirect’ pathway, which passes first to the external segment
of the globus pallidus (GPe) via striatal projection neurones that contain both GABA and
enkephalin, then from GPe to the subthalamic nucleus (STN) via a purely GABAergic pathway,
and finally to the output nuclei via an excitatory, probably glutaminergic, projection from the
STN.121 It should be apparent that dopamine D1 receptors are primarily present on the medium
spiny neurones, forming the ‘direct’ pathway, whereas dopamine D2 receptors are primarily
























Figure 1.2 Schematic diagram of the circuitry and neurotransmitters of the basal ganglia-
thalamocortical circuitry, indicating the parallel ‘direct’ and ‘indirect’ pathways from the
striatum to the basal ganglia output nuclei in a normal situation. Inhibitory neurons are
shown as filled symbols, excitatory neurons as open symbols. Abbreviations: DA,
dopamine; D1, dopamine D1 receptor; D2, dopamine D2 receptor; A2A, adenosine A2A
receptor; enk, enkephalin; GABA, γ-aminobutyric acid; GPe, external segment of globus
pallidus; GPi, internal segment of globus pallidus; glu, glutamate; PPN,
pedunculopontine nucleus; SNc, substantia nigra pars compacta; SNr, substantia nigra
pars reticulata; subst P, substance P; STN, subthalamic nucleus; Thal, thalamus. Adapted
from references 121-123.
Considerable evidence indicates that shifts in the balance between the activity in the
‘direct’ and ‘indirect’ striatal output pathways and the resulting alterations in the output of the
SNr and the GPi may account for the hypo- and hyperkinetic features of basal ganglia movement
disorders. In summary, excessive inhibition of GPe within the indirect pathway leads to
disinhibition of the STN, which in turn provides excessive excitatory drive to basal ganglia
output nuclei (GPi/SNr), thus leading to excessive thalamic inhibition. This is reinforced by
reduced inhibitory input to GPi/SNr through the direct pathway. Overall these effects are
postulated to results in a reduction in the usual reinforcing influence of the motor circuit upon
cortically initiated movements.123 (For more reviews and references see ref. 117, 124-126).
Based on the altered neuronal activity in the ‘motor’ circuit in Parkinson’s disease, it
seems that parkinsonism symptoms can be treated by restoring the right balance between the
activity in the ‘direct’ and ‘indirect’ pathways.
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Although the exact cause of the progressive degeneration of nigrostriatal dopamine
neurons in Parkinson’s disease is still unknown, several mechanisms were proposed to explain
the cell damaging processes at the molecular level that ultimately cause Parkinson’s disease.127
These mechanisms, which are probably related by interacting mechanisms, include:
(1) excitotoxic mechanism,128 (2) mitochondrial toxins,129 and (3) oxidative stress.130
There is considerable body of (indirect) evidence which makes oxidative stress one of the
best accepted hypothesis for explaining the cause of Parkinson’s disease. For example, the
Fe(II)/Fe(III) ratio in the substantia nigra is shifted from 2:1 in the normal brain to 1:2 in
Parkinsonian brain.131,132 In the Parkinsonian brain several enzymes which constitute the
antioxidative defence mechanisms (glutathione peroxidase, catalase) have a decreased activity,
while the activity of superoxide dismutase is increased, relative to the normal brain.133
Furthermore, specific products of radical damage, such as lipid hydroperoxides, were detected at
a 10-fold increased level in the Parkinsonian brain.134
1.5.1.2 Current treatment of Parkinson’s disease
As Parkinson’s disease is associated with a loss of dopamine, it is commonly treated with
drugs, which replace or supply dopamine. Since dopamine itself cannot pass the blood-brain
barrier, the most commonly used therapy is levodopa (L-DOPA), a precursor of dopamine. A
complication of long-term treatment with L-DOPA, however, is the development of rapid
fluctuations in clinical state where the patient switches suddenly between mobility and
immobility; this phenomenon is known as the ‘on-off effect’.135,136 This effect might be caused
by the loss of feed-back mechanisms.
An alternative approach to the treatment with L-DOPA is the use of drugs that mimic the
action of dopamine. Treatment with dopamine-agonists, such as bromocriptine (15),137
pergolide,138,139 and lisuride,138,140 has some advantages over treatment with L-DOPA.
Dopamine agonists are effective in patients in the advanced stages of Parkinson’s disease,
unlike L-DOPA, because their action at postsynaptic dopamine receptors is unaffected by the
lack of dopamine producing nerve cells.
Furthermore, there is an increasing interest in the direct effect of dopamine agonists to be
potential neuro-protective agents. A number of studies in biologic and non-biologic systems
have shown that dopamine agonists have antioxidant effects and can trap a variety of radical
species.141-143 Theoretically, such a protective effect might result from (a) a decrease in L-DOPA
application, as L-DOPA itself may cause oxidative stress,144 (b) stimulation of dopamine
autoreceptors resulting in decreased dopamine synthesis, release, and turnover, as dopamine



































Chart 1.8 Chemical structures of bromocriptine (15), ABT-431 (16), dihydrexidine (17), ropinirole
(18), and pramipexole (19).
Drug therapies or therapies which are in clinical development,146-149 nowadays, include
treatment with (prodrugs of) dopamine receptor agonists that are either selective for the
dopamine D1 receptor, such as ABT-431150 (16) and dihydrexidine151,152 (17), or are selective for
the dopamine D2/D3 receptor subtypes, such as ropinirole153 (18) and pramipexole154,155 (19). An
ideal antiparkinsonian treatment may require stimulation of both D1 and D2 dopamine
receptors.156 Literature shows that antiparkinsonian effects can be exerted either by a dopamine
D1 receptor agonist alone or by a dopamine D2 receptor agonist alone, whereas hyperactivity and
aggressiveness manifested by dopamine receptor agonists require co-activation of the D1 and D2
receptors. The antiparkinsonian effect can be dissociated from the adverse effect by therapeutic
strategy. It is implied that imbalances in activation of the D1 and D2 receptors may provide a
favourable approach for long-term treatment of parkinsonian patients with dopamine
drugs.157,158 Potent dopamine D1 receptor agonists with an intermediate half-life may prove to be
better adjuncts in the treatment of Parkinson’s disease, because stimulation of the dopamine D1
receptor may provide a better integration of neural inputs to the internal segment of the globus
pallidus (referred to as the basal ganglia output) compared with L-DOPA and selective
dopamine D2 receptor agonist.159,160 A drug with affinity for both the dopamine D1 and D2
receptors is apomorphine, which can be a good tool in restoring the imbalances in activation of
the D1 and D2 receptors in Parkinson’s disease.
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Dopamine receptor agonists used in the therapy against Parkinson’s disease often possess
phenolic or catecholic moieties, which lead to low oral bioavailabilities for these compounds
since they undergo considerable metabolic degradation in the liver.161 Because of the low oral
bioavailability of hydroxylated compounds, there has been a lot of interest in the development
of prodrugs of such compounds, thereby circumventing the metabolic degradation.
Other approaches, some of which are still in clinical development, include restoration of
the acetylcholine-dopamine balance in the basal ganglia, neuronal nicotinic receptor agonists,
neurotrophic immunophilins, dopamine transport inhibitors, COMT-inhibitors, and adenosine
A2A receptor antagonists.162,163 Also surgical therapies are used or under development, including
stereotactic thalamotomy, continuous electric thalamus stimulation,164 posteroventral
pallidotomy and transplantation of embryonal substantia nigra cells.
1.5.2 Schizophrenia
1.5.2.1 Pathology of schizophrenia
Schizophrenia is a psychotic disorder of unknown aetiology in which patients suffer from
a cluster of symptoms which may include both positive (delusions, hallucinations, disordered
thoughts, and disorganised speech) and negative (flat effect, anhedonia, social withdrawal,
emotional detachment, cognitive deficits, and poverty of speech) symptoms. This disease, which
is relatively common (lifetime prevalence rate ~1 %), usually strikes its victims during
adolescence or early adulthood. Since occupational and social function is severely affected,
often leading to institutionalisation, the cost to society is very high.165 Unfortunately, it is very
difficult to diagnose schizophrenia and many different diagnostic systems have so far been
developed. Moreover, there are strong indications that schizophrenia is not a homogeneous
disorder, but rather consists of subgroups.166
Although there has been extensive research during several decades, still no definite
explanation for the development of schizophrenia in man can be given. There is still a
controversy between the very diverse theories to explain the development of the disease. It is
generally accepted that genetic predisposition plays a significant etiological role in
schizophrenia.167 Although there has been a lot of research for finding genes for schizophrenia
this search has not been successful yet. Crocq et al.168 found an association between
schizophrenia and homozygosity at the dopamine D3 receptor gene. However, Yang et al.169
found that this association was not present in schizophrenics. These two studies show that more
research is necessary to find genes. Other etiological factors in schizophrenia are infection and
autoimmunity,170 and obstetric complications.171 Also theories involving neurochemical
alterations are related to the pathogenesis of schizophrenia. From this point of view the
dopamine hypothesis has provided a framework for understanding the disease and proposing
approaches to the treatment of schizophrenia. This hypothesis suggests that schizophrenia
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results from increased dopaminergic neurotransmission and that treatments which decrease
dopaminergic function will alleviate psychotic symptoms.165 This dopamine hypothesis prevails
despite much criticism and qualification. In addition to dopamine, there has been increased
interest in other neurotransmitters that are hypothesised to play a role in schizophrenic
pathophysiology through their interaction with dopamine or in their own right. The principal
candidates in recent years have been serotonin, noradrenaline, glutamate and the neuropeptides
cholecystokinin and neurotensin.172
Another line of research is focused on the neurobiological development of the human
brain in relation to schizophrenia. It has been hypothesised that schizophrenia is due to
abnormal neurodevelopment, which results in a static encephalopathy that usually becomes
manifest in adolescence. This abnormal development leads to morphological deviations such as
enlarged or reduced brain structures, a disrupted communication between different brain
structures, alterations in neuron density or decreased neuron size, and abnormal neuronal
migration or differentiation.173
1.5.2.2 Current treatment of schizophrenia
The first neuroleptic drug to be developed was chlorpromazine (20) in 1952, which
belongs to the group of the phenothiazines. Reserpine (21) was the second drug, which was
introduced into the psychiatric practice. Although it is a potent anti-psychotic drug, its side
effects are so strong that it is hardly used as an anti-psychotic drug anymore. Another line of
research was the development of butyrophenones. An important representative of this series of
























Chart 1.9 Chemical structures of chlorpromazine (20), reserpine (21), haloperidol (22).
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Since the discovery of the first antipsychotic agents researchers have tried to classify the
different drugs. First the drugs were classified according to the therapeutic profile of individual
drugs, later the side effects were used to classify the anti-psychotic drugs. Nowadays, anti-
psychotic drugs are divided into two groups. The typical (first generation) anti-psychotics
include a variety of phenothiazine and butyrophenone type compounds (with chlorpromazine
(20) and haloperidol (22), respectively, as well known examples), and have in common their
(potent) antagonism at the dopamine D2 receptor. These anti-psychotics are especially active
against the positive symptoms of schizophrenia and usually show serious extrapyramidal side-
effects (EPS) and elevation of serum prolactin levels. An atypical anti-psychotic is defined as a
drug that has anti-psychotic efficacy, with minimal EPS and elevation of serum prolactin levels,
and that does not cause tardive dyskinesia. An additional effect of the atypical anti-psychotics is
its efficacy against negative symptoms (for review see ref. 166).
The prototypical atypical anti-psychotic drug, nowadays, is clozapine (23). The drug has
affinity for a variety of receptor subtypes; i.e. dopamine, serotonin, histamine, muscarine and
noradrenaline receptors.174 Because of the variety of binding affinities of clozapine (23), new
drugs were tried to be developed with a selectivity for one of the above-mentioned receptors. So,
amongst others, selective dopamine and 5-HT2A receptor antagonists were developed, but none
of these drugs has reached the market yet.
Clozapine (23) shows that the atypicallity of a neuroleptic drug is explained by its affinity
for more than one receptor subtype, and that no single hypothesis effectively explains the
atypical character. Currently on the market are the following atypical anti-psychotics: clozapine
































Cocaine and amphetamine are powerful psychostimulants and widespread abuse of these
drugs creates a major problem in society. Two characteristics of drug addiction are the
compulsive nature of substance use and the high propensity for relapse. Relapse is, in fact, so
prevalent that attempts to stop using drugs often lead to repeated cycles of detoxification
followed by a return to compulsive substance use.175 The craving for drugs in an addict is driven
not only by the pain and discomfort of withdrawal, but also by the expected rewarding effect of
the drug. Craving can even be elicited by stimuli previously associated with taking the drug.
Over the past several years, researchers have begun to work out the neurochemical substrates of
such conditioned responses. Several studies indicate that the brain neurotransmitter dopamine
plays a pivotal role in the ‘reinforcing’ effects of many drugs of abuse, including cocaine.
Cocaine causes large increases in the amount of dopamine available to stimulate dopamine
receptors. These increased levels are probably responsible for the ‘reinforcing’ effects, meaning
that an addict is more likely to seek cocaine in the future.
The dopamine D3 receptor is mainly expressed in the limbic regions of the brain,
including the nucleus accumbens, olfactory tubercle, the ventral pallidum and the
amygdala.19,176 The nucleus accumbens has been implicated in motivated behaviours such as
drug self-administration and conditioned-cue preference (CCP).177 The limbic region-specific
expression of the dopamine D3 receptor has led to the speculation that this receptor may be
involved in responses to psychostimulants. A number of different studies have shown that
cocaine self-administration is attenuated by the co-administration of moderately selective
dopamine D3 receptor agonists, suggesting the potential importance of dopamine D3 receptors
for this behaviour.116,178,179 Using a genetic approach Xu177 found that dopamine D3 receptor
mutant mice exhibit increased sensitivity to amphetamine in the CCP paradigm. This finding
suggests that the dopamine D3 receptor is involved in behavioural responses to the rewarding
effect of amphetamine and that dopamine D3 receptor-associated mechanisms can either
attenuate the positive effect or disrupt the conditioning process whereby the neutral cues in the
conditioning environment become associated with this effect.177 Furthermore, Staley and
Mash180 found in cocaine overdose victims, as compared with age-matched and drug-free
control subjects, that the number of [3H]-(+)-7-OH-DPAT binding sites was elevated. This
demonstrates that adaptive changes in the dopamine D3 receptor in the reward circuitry of the
brain are associated with chronic cocaine abuse. These results suggest that the dopamine D3
receptor may be a useful target for drug development. No medications have reached the clinical
stage or the market yet.
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1.6 Oral bioavailability of dopamine receptor agonists
Many dopamine receptor agonists, both of natural and synthetic origin, contain the
catecholethylamine structure of dopamine embedded within them. The clinical utility of
catechol and phenol-containing dopamine receptor agonists has been limited by their relatively
low selectivity for presynaptic versus postsynaptic dopamine receptors, their low oral
bioavailability and, consequently, their short duration of action. The catechol and phenol rings
provide optimal sites for metabolism as well as conjugation and excretion.181 To circumvent the
problem of the low oral bioavailability of dopamine receptor ligands, synthesis of bioisosteres or
prodrugs of the phenolic compounds could be useful.
1.6.1 Bioisosteric replacement
Throughout its development, there has been a number of different definitions proposed for
bioisosterism. Friedman defined bioisosterism as the relationship of compounds, which fit the
broadest definition of isosteres and have the same type of biological activity. Erlenmeyer was
more restricted in his definition and he postulated that isosteres are atoms, ions or molecules in
which the peripheral layers of electrons can be considered to be identical. Hansch tried to be
less vague and defined bioisosterism as compounds causing identical biochemical or
pharmacological response in a standard test system. The system might be an enzyme,
membrane, mouse or man. Finally, Burger suggested an expanded statement which takes into
account biochemical views of biological activity. Bioisosteres are compounds or groups that
possess near-equal molecular shapes and volumes, approximately the same distribution of
electrons, and which exhibit similar physical properties such as hydrophobicity. Bioisosteric
compounds affect the same biochemically associated systems as agonists or antagonists and
thereby produce biological properties that are related to each other. For a review on these
definitions see ref. 182.
A number of different bioisosteric replacements can be found in literature, but here only
the ones important for the experiments described in this thesis are given. (for review see ref.
182). A -CH=CH- group in a benzene moiety is replaced by divalent sulphur (-S-) giving a
thiophene. The most popular bioisosteric substituents for the phenolic hydroxyl are
methanesulfamide (CH3SO2NH-), hydroxymethyl (HOCH2-) or hydroxyisopropyl (HOC(CH3)2),
various amide groups (-NHCHO, -NHCOCH3, -NHCOC6H5), methanesulfamidomethyl
(CH3SO2NHCH2-), dimethylaminosulfonamide ((CH3)2NSO2NH-), and other with an ionizable
proton next to, or near an aromatic ring. These groups should be not much larger than hydroxyl
or they should have the same approximate acidity range, form hydrogen bonds and, on occasion,
redox systems, in conjugation with a para-OH.
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The structure of a catechol itself can be replaced by analogous heterocycles in various
derivatives. All these compounds share the ability to chelate metal atoms and to form hydrogen-
bonded second rings, the benzimidazole imitates this by way of a covalent ring structure.182 A
successful bioisosteric replacement of a phenol or a catechol moiety is the 2-aminothiazolyl
moiety. Active dopaminergic compounds which possess such a moiety are B-HT 920 (32)183 and
pramipexole (19).146,154,155
One apparent shortcoming of bioisosterism was that what seemed to be a solid rule in one
series of structurally related compounds failed to work out in a series with different overall
structural characteristics. Experiments to rationally design a drug structure, may have disturbed
one of several parameters that had proved to be necessary for inducing a given biological
activity. Such parameters include size and bond angles, ability to form hydrogen bonds, pKa,
chemical reactivity, hydrophilicity, lipophilicity, and also the metabolic fate of the compounds
to be prepared. One will rarely seek to obtain a drug with completely identical properties but
almost always try to improve efficacy and specificity and decrease side effects and/or toxicity. 182
1.6.2 Pro-drugs of dopamine receptor agonists.
A prodrug is a pharmacologically inactive derivative of a parent drug molecule that
requires spontaneous or enzymatic transformation within the body in order to release the active
drug, and that has improved delivery properties over the parent drug molecule. A molecule with
optimal structural configuration and physico-chemical properties for eliciting the desired
therapeutic response at its target site does not necessarily possess the best molecular form and
properties for its delivery to its point of ultimate action. Prodrugs are designed to overcome
pharmaceutically and/or pharmacokinetically based problems associated with the parent drug
molecule that would otherwise limit the clinical usefulness of the drug. In the design of a
prodrug several criteria should be considered: (1) what functional groups on the parent drug
molecule are sensitive to chemical derivatisation, (2) what mechanisms and systems are
available in the organism for the required bioactivation of the prodrug, (3) synthesis and
purification of the prodrug should be relatively simple, (4) the parent drug molecule must be
regenerated from the prodrug in vivo, (5) toxicity of the transport group of the prodrug as well as
of the prodrug per se must be considered.
Application of prodrugs has involved (1) enhancement of bioavailability and passage
through various biological barriers, (2) increased duration of pharmacological effects,
(3) increased site-specificity, (4) decreased toxicity and adverse reactions, (5) improvement of
organoleptic properties and (6) improvement of stability and solubility properties.184
Since a lot of the dopamine receptor agonists possess catechol or phenol moieties, the




1.7 Functional models used to study dopamine receptor ligands
There are a large number of generally accepted in vitro and in vivo test models available
for the evaluation of centrally acting dopamine receptor agonists and antagonists. These models
give information about the effect on pre- and postsynaptic dopamine receptors. The models for
postsynaptic receptors can also be used to determine the involvement of different receptor
subtypes on the effect. In this part only the in vivo models used in this thesis are discussed
briefly.
1.7.1 Brain microdialysis
On-line brain microdialysis is an in vivo sampling technique in freely moving animals.188
The technique is based on the dialysis principle in which a membrane, permeable to water and
small molecules, separates two fluid compartments. The tubular membrane is constantly
perfused with the extracellular fluid by diffusion in both directions. A microdialysis probe
typically consists of a cylindrical dialysis membrane that is connected with in- and outlet tubes.
The length of the membrane is adjusted to the brain region studied. Neurotransmitters and their
metabolites in the dialysates can be determined by the use of HPLC techniques. The
extracellular level of a given neurotransmitter that is determined by microdialysis is supposed to
reflect the overflow of neurotransmitter. Using the microdialysis technique the dopamine D2
receptor agonistic properties of the compounds can be monitored, as the release of dopamine is
under the control of dopamine D2 autoreceptors.189 Dopamine agonists decrease and antagonists
increase dopamine levels as measured by microdialysis.
1.7.2 Locomotor activity in reserpinised rats
The postsynaptic agonistic effects of dopaminergic agents can be determined in rats by
measuring the effect on locomotor activity. These experiments are performed in rats which had
been treated 18 h beforehand with reserpine. Reserpine reduces the monoamine levels by
inhibiting the transport system of the storage granule membrane and thereby the nerve endings
lose their ability to concentrate and store the amine.190 After 18 h there is no endogenous
dopamine present and the locomotor activity measured after administration of a dopamine
receptor agonist is solely caused by the agonist.
1.7.3 Behavioural characteristics in reserpinised rats
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During the locomotor activity experiments also the behavioural characteristics were
observed. With these observations an indication can be given about which receptors are
important for the behaviour. The dopaminergic stereotyped behaviour can be divided into two
groups, namely behaviour caused by dopamine D1-receptors (rearing) and dopamine D2
receptors (licking and sniffing).191 Indications for the serotonergic behavioural syndrome are flat
body posture and lower lip retraction which is caused by 5-HT1A receptor agonists.192
1.8 Scope of the thesis
The Department of Medicinal Chemistry at the University of Groningen has a long
tradition in the design, synthesis, and pharmacological evaluation of drugs acting at the central
nervous system. During the last 15 years research has been focused in particular on
2-aminotetralin-derived and structurally related compounds, such as
octahydrobenzo[f]quinolines, hexahydronaphthoxazines and tetrahydrobenzopyranoxazines,
with activity at dopamine, serotonin or melatonin receptors (e.g. see refs. 193-199). Examples of
dopamine receptor ligands that have been developed within the department are the dopamine D3
receptor preferring agonists (R)-7-OH-DPAT and PD 128907,200 and the dopamine D2 receptor
preferring agonist N-0923,201 which is currently undergoing clinical trials for the treatment of
Parkinson’s disease.
All the above mentioned compounds have the same problem, namely, they undergo
considerable deactivation by means of glucuronidation in the liver, because of their phenol
moiety. This thesis deals with the synthesis and pharmacological evaluation of dopamine
receptor ligands, which were designed to possess a higher oral bioavailability than the currently
known dopamine receptor agonists. The main goal was to bioisosterically replace the phenol
moiety of 2-aminotetralins and hexahydronaphthoxazines with a thiophene moiety.
Apomorphine and three of its analogues were tested to determine their relative oral
bioavailabilities in a search for good targets for treatment of Parkinson’s disease. Also a novel
prodrug of hydroxylated 2-aminotetralins has been tested to find compounds with a better oral
bioavailability, as compared to hydroxylated 2-aminotetralins.
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